WuXi Biologics is helping Vir Biotech develop Covid-19 antibodies
San Francisco’s Vir Biotech is enlisting one of China’s biggest biologics contract manufacturing organizations to help develop new antibody therapies to try to treat Covid-19 infections. The immunology-focused biotech said a number of its monoclonal antibodies can bind to the novel coronavirus and decided to team up with Wuxi Biologics to accelerate the development of a potential therapy in response to the global threat.
The Shanghai-based biologics developer will be in charge of developing and manufacturing Vir’s treatments, a process that typically takes 12 to 18 months, CEO Chris Chen told STAT.
What’s in it for Wuxi Biologics? The deal gives the company the right to commercialize the therapies in China, while Vir retains the rights for the rest of the world.
“With the new technology platform we are developing, we target 6-7 months for the IND package [ready for clinical trial]. The commercialization process would depend on the clinical data. We can commercialize the product as early as the clinical data is favorable, as short as 1 to 2 years,” Chen added.
The Shanghai-based biologics developer will be in charge of developing and manufacturing Vir’s treatments, a process that typically takes 12 to 18 months, CEO Chris Chen told STAT.
What’s in it for Wuxi Biologics? The deal gives the company the right to commercialize the therapies in China, while Vir retains the rights for the rest of the world.
“With the new technology platform we are developing, we target 6-7 months for the IND package [ready for clinical trial]. The commercialization process would depend on the clinical data. We can commercialize the product as early as the clinical data is favorable, as short as 1 to 2 years,” Chen added.
.png)
No hay comentarios:
Publicar un comentario